drugset
Drugs / ALVAC-CEA vaccine
last change Nov 2004 re-read 3 minutes ago

ALVAC-CEA vaccine

also known as CEA-Avipox vaccine

Vaccine

Developed for
breast cancer · esophageal cancer · gastric cancer · lung cancer · malignant pancreatic neoplasm
Investigated by
Georgetown University · National Cancer Institute (NCI)

Trials 1

today NCT00003125 · Ph 2
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00003125 Jan 1998 → Nov 2004 breast cancer, esophageal cancer, gastric cancer, lung cancer +1 Georgetown University Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ALVAC-CEA vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003125 ↗
Known as CEA-Avipox vaccine “ALVAC-CEA vaccine (CEA-Avipox vaccine) intramuscularly (IM)” NCT00003125 ↗
Modality Vaccine “ALVAC-CEA vaccine” NCT00003125 ↗
Route Intramuscular “ALVAC-CEA vaccine (CEA-Avipox vaccine) intramuscularly (IM)” NCT00003125 ↗